Conexeu Sciences Inc. — Form 8-K Summary
Reporting event: October 15, 2026; filed October 20, 2026. This 8-K reports unregistered equity issuances and a private placement. It does not provide a reporting-period income statement, balance sheet, or cash flow statement.
Financing and key financial terms
- On October 15, the Company issued 1,333,333 Units to three accredited investors at $3.00 per Unit, raising gross proceeds of $3,999,999. Each Unit includes one common share and a warrant to buy one share at $3.00, exercisable for 24 months.
- The Company issued 250,000 Special Warrants to two Canadian accredited investors at $3.00 each, raising $750,000. Each is to convert automatically into one share and one warrant, without further payment, upon the earlier of receipt of the specified British Columbia prospectus or February 16, 2027.
- Management and director subscribers committed $250,002 for 83,334 Units, but the securities have not been issued and the funds remain in escrow pending stockholder approval under Nasdaq Listing Rule 5635(c). If approval is denied, the securities will not be issued and the funds will be returned.
- The Company said proceeds from the Units and Special Warrants are intended for working capital and general corporate purposes. Including $1,250 received from warrant exercises described below, the disclosed gross proceeds received total $4,751,249; the additional $250,002 is conditional and escrowed.
- Other reported issuances included 33,500 shares to a consultant on October 5 at a deemed $3.57 per share; 1,667 shares to a consultant on September 29 at a deemed $3.77; 6,500 shares to consultants on September 22 at a deemed $4.75; and warrant exercises producing 750,000 shares for $750 on September 25 and 500,000 shares for $500 on September 14.
Financial performance and comparison
The filing provides no revenue, profit, operating cash flow, margins, debt, liquidity balances, or financial guidance. It is a securities-issuance disclosure rather than a periodic financial report, so operating results and comparisons with prior periods are not available here.
The filing states that the issuances since the last periodic report exceeded 5% of the Company’s issued and outstanding common shares. It does not provide the share-count denominator needed to quantify the resulting dilution.
Other material terms, risks, and contingencies
- The Company agreed to file a resale Form S-1 covering specified shares and warrant shares, excluding securities held by affiliates, no later than the 35th calendar day after October 15, 2026. If it misses the deadline, it owes affected subscribers cash damages equal to 2.0% of their aggregate subscription price.
- Some warrant holders have beneficial ownership limits of 4.99% or 9.99% for warrant shares.
- The securities are described as restricted securities. The filing relies on exemptions or exclusions from Securities Act registration for the reported issuances.
- The filing’s opening aggregate says 1,290,000 common shares were issued from September 14 through October 15, but the listed individual share issuances total 1,291,667. This difference is not reconciled in the filing text.
Important facts for investors to verify
- Whether stockholders approve the 83,334 management and director Units, and whether the $250,002 escrow is released or returned.
- Whether the Company files the resale Form S-1 by the stated deadline and whether any liquidated damages become payable.
- The eventual conversion of the Special Warrants and the number of shares and warrant shares issued, including the resulting dilution and outstanding share count.
- The discrepancy between the stated aggregate of 1,290,000 shares and the 1,291,667 shares implied by the itemized issuances.
- How the proceeds are used and the Company’s financial condition, which are not detailed in this 8-K.